Articles

Pharma bets on PD-1/VEGF bispecifics: Is lung cancer the wrong target?

While many drugmakers are focused on lung cancer for PD-1/VEGF bispecifics, emerging evidence shows the liver may offer higher value. This analysis covers the mechanism, key players, and strategic implications for pharma teams.

STAT+: What stripping civil service protections for thousands of federal workers will mean for HHS

President Trump's executive order reclassifying thousands of federal workers under Schedule F removes civil service protections for senior HHS staff, including at FDA, NIH, and CDC. This analysis explains the policy change, its implications for pharmaceutical regulatory processes, and what BD teams should monitor next.

Otsuka kidney drug data and Pfizer AI deal: Biopharma deal tracker

Otsuka released Phase 3 data for Voyxact in IgA nephropathy, showing slowed kidney function decline but leaving room for competitors. Pfizer struck an AI deal, signaling increased automation in drug development.

FDA Priority Review Voucher Program: Will Makary's Initiative Survive?

The FDA's National Priority Voucher program, championed by former Commissioner Makary, faces uncertainty amid congressional investigations and industry pushback. This analysis examines the program's survival prospects and impact on drug review timelines, voucher sales, and rare disease incentives.

OHRP Underfunding Risks Human Subject Protection in 2026

The Office for Human Research Protections (OHRP) is now operating with only a fraction of its mandated staff, creating risks for oversight of human subject safety under The Federal regulations at 45 CFR 46. Pharma strategy and BD teams should prepare for potential delays in regulatory guidance and increased reliance on institutional IRBs.

Tip Sheet GLP-1s and Cancer: Key Insights for Pharma BD and Investors

This tip sheet analyzes recent findings on GLP-1s and cancer risk, initiatives to expand cancer care access in Washington State, and the rise of nursing-led oncology research. It provides actionable intelligence for pharma business development, investors, and analysts.

Grail’s Galleri Trial Missed Its Primary Endpoint: What BD Teams and Investors Need to Know

Grail’s NHS-Galleri trial did not show a statistically significant reduction in late-stage cancers. However, a substantial reduction in stage 4 cancers and a shift to stage 3 diagnoses reveal a more nuanced picture for investors and BD teams.

ADC Specialist Sinks on Safety Concerns: What Pharma Teams Need to Know

Shares for ADC Therapeutics fell more than 50% after a Phase 3 trial observed a death rate that at least one analyst believes “may be difficult to accept” for doctors and regulators. The safety signal raises critical questions for the ADC class and competitive landscape in blood cancer.

FDA Voucher Program Under Fire: Pharma and Patient Groups Demand Pause

Drug companies and patient groups are urging the FDA to pause the Commissioner's National Priority Voucher (CNPV) pilot program, which offers dramatically faster drug reviews but has drawn criticism for enabling political influence. The program, which can reduce review times from 10-12 months to 1-2 months, is under investigation by lawmakers concerned about corruption.

Top 10 Pharmaceutical Stocks to Buy for June 2026: A B2B Analysis

This analysis identifies the top 10 pharmaceutical stocks to buy for June 2026, focusing on catalysts, sales growth, and regulatory tailwinds from the EMA. It provides actionable insights for BD teams, investors, and analysts seeking high-upside opportunities.

STAT+: RFK Jr.’s second year: Vacancies, not vaccines

RFK Jr.’s second year at HHS has been defined by leadership vacancies and policy shifts at the NIH, not vaccine debates. For pharma BD and strategy teams, the key signal is the implementation of Schedule F, which could reshape federal hiring and grant oversight.

HHS Confirms Americans with High-Risk Ebola Exposures Will Have Access to Experimental Therapy MBP-134

HHS has confirmed that Americans with high-risk Ebola exposures in the current Central African outbreak will have access to the experimental monoclonal antibody treatment MBP-134 from Mapp Biopharmaceuticals. This decision, based on promising animal data, signals a potential shift in emergency use policy and creates competitive benchmarking opportunities for pharma teams.

FDA Extends Comment Period for Real-Time Clinical Trials Pilot, AI Use in Studies

The FDA has extended the public comment period for its Real-Time Clinical Trials (RTCT) pilot and the associated Request for Information on AI-enabled optimization of early-phase trials. This move signals the agency's commitment to integrating AI into clinical trial oversight, with implications for drug development speed, cost, and regulatory strategy.

Kairos Pharma Highlights CL-741 Acquisition and 2026 Clinical Milestones: A Strategic Analysis for Pharma Decision-Makers

Kairos Pharma has signed a term sheet to acquire CL-741, a clinical-stage oncology asset, and outlined key 2026 milestones including a Phase 1 trial initiation. This article provides a competitive benchmarking analysis for pharma strategists and investors, covering the deal's rationale, pipeline impact, and what to watch next.

China: The Innovation Factor – Implications for Pharma BD and Investors

China has emerged as a global innovation powerhouse, now leading in 37 of 44 critical technologies. This article examines what this means for pharmaceutical deal-making, investment decisions, and competitive strategy for BD teams and executives.

STAT Supreme Court backs generic drugmaker in 'skinny labeling' case: Implications for pharma BD and investors

The U.S. Supreme Court unanimously ruled that Hikma Pharmaceuticals did not infringe Amarin's patents through its skinny-labeled generic version of Vascepa. This decision clarifies the Hatch-Waxman skinny-label safe harbor, reducing litigation risk for generic entrants and reshaping competitive dynamics for branded cardiovascular drugs.

Daraxonrasib Pancreatic Cancer: What RevMed’s Breakthrough Means for Patients and Pharma

Revolution Medicines’ daraxonrasib nearly doubled median survival in a Phase 3 trial for pancreatic cancer, offering a new standard of care. This article analyzes the clinical data, side effect profile, and competitive implications for pharma teams.

AI Titans Push Congress for DNA Safeguards: Implications for Biotech Strategy

OpenAI, Anthropic, Inceptive Nucleics, and Grail are urging Congress to enact DNA safeguards, signaling a shift in the regulatory landscape for genomic data. This article analyzes the competitive and strategic implications for biotech firms.

Pharma Pulse: 340B Uncertainty, Drug Shortages, and Wegovy's Global Debut

A Bluesight survey highlights hospital pharmacy anxieties over 340B program uncertainty and ongoing drug shortages. Meanwhile, Novo Nordisk launches the Wegovy pill in the UAE, signaling a global expansion strategy amid supply challenges.

Revolution Medicine Pancreatic Cancer: Demand Surge Strains Daraxonrasib Access

Revolution Medicines' daraxonrasib has shown a dramatic overall survival benefit in pancreatic cancer, but patient demand is overwhelming the expanded access program. For pharma strategists, the supply-demand imbalance signals potential launch revenue upside and commercial execution risk.